Table 5.

Differentially expressed pathways and top ten differentially expressed pathways in the control with 2.2 nm and 3.5 nm MPA-capped CdTe QD treatment

Term	Pathway ID	Input number of gene	Background number of gene	Corrected P-value
2.2 nm CdTe QDs vs control
Influenza A	rno05164	6	151	0.00391411
Staphylococcus aureus infection	rno05150	3	45	0.018418904
Herpes simplex infection	rno05168	5	176	0.018418904
Cytosolic DNA-sensing pathway	rno04623	3	46	0.018418904
3.5 nm CdTe QDs vs control
Staphylococcus aureus infection	rno05150	23	45	3.86−8
Antigen processing and presentation	rno04612	21	73	0.000182151
Chagas disease (American trypanosomiasis)	rno05142	23	87	0.000182151
Toll-like receptor-signaling pathway	rno04620	22	81	0.000182151
Tuberculosis	rno05152	31	148	0.000182151
Leishmaniasis	rno05140	19	64	0.000182151
Cytokine–cytokine receptor interaction	rno04060	36	189	0.000182151
Osteoclast differentiation	rno04380	26	113	0.000182151
Cell-adhesion molecules	rno04514	29	136	0.000182151
Pertussis	rno05133	18	61	0.000224868

Abbreviations: MPA, 3-mercaptopropionic acid; QD, quantum dot.